NDA 021964 · Salix Pharms
Relistor
Methylnaltrexone Bromide · Subcutaneous
NovelLast checked: Nov 19, 2026Latest source record: Mar 14, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Apr 24, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
57
17 Phase 3, 2 recruiting
FAERS reports
1,520
905 serious, 335 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 1, 2024.
• RELISTOR is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.1 ) • RELISTOR injection is indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care. ( 1.2 ) 1.1 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. 1.2 Opioid-Induced Constipation in Adult Patients with Advanced Illness RELISTOR injection is indicated for the treatment of OIC in adult patients with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care.
Mechanism: Methylnaltrexone is a selective antagonist of opioid binding at the mu-opioid receptor. As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted. This allows methylnaltrexone to function as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids without impacting opioid-mediated analgesic effects on the central nervous system (CNS).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 29, 2014 Supplement 10 · Efficacy LabelLetter
- Apr 24, 2008 Original approval · Type 1 - New Molecular Entity NovelReviewLetter
3 products under this application
- RELISTOR · METHYLNALTREXONE BROMIDE 12MG/0.6ML (12MG/0.6ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
- RELISTOR · METHYLNALTREXONE BROMIDE 12MG/0.6ML (12MG/0.6ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
- RELISTOR · METHYLNALTREXONE BROMIDE 8MG/0.4ML (8MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Methylnaltrexone" as an intervention, any sponsor and status, largest first.
- Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced ConstipationPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00804141 · 1,040 participants · Start Dec 3, 2008 · Primary completion Sep 20, 2010
Drug: N-methylnaltrexone bromide (MOA-728) · For: Constipation
Sites: Birmingham, Alabama; Chandler, Arizona; Mesa, Arizona · 120 sites in all
- A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant PainPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01186770 · 804 participants · Start Sep 1, 2010 · Primary completion Sep 8, 2011
Drug: Methylnaltrexone; Placebo · For: Opioid-Induced Constipation
Sites: Raleigh, North Carolina · 2 sites in all
- Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac RepolarizationPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01363323 · 546 participants · Start Nov 2004 · Primary completion Jan 2005
Drug: Methylnaltrexone (MNTX); Methylnaltrexone (MNTX) and 3 more · For: Healthy Volunteers
Sites: Tarrytown, New York
- Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00401375 · 524 participants · Start Oct 31, 2006 · Primary completion Feb 29, 2008
Drug: Methylnaltrexone; Placebo · For: Post-Operative Ileus (POI)
Sites: Tarrytown, New York
- Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative IleusPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00387309 · 495 participants · Start Dec 2006
Drug: Methylnaltrexone (MOA-728) · For: Post Operative Bowel Dysfunction
Sites: Mobile, Alabama; Fort Smith, Arkansas; Chula Vista, California · 92 sites in all
- Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant PainPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00529087 · 460 participants · Start Aug 2007 · Primary completion Dec 2008
Drug: N-methylnaltrexone bromide (MOA-728) · For: Constipation
Sites: Mobile, Alabama; Sun City, Arizona; Tucson, Arizona · 78 sites in all
- A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia RepairPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00528970 · 374 participants · Start Oct 17, 2007 · Primary completion Feb 5, 2008
Drug: MOA-728; Placebo · For: Ileus
Sites: Benton, Arkansas; Colton, California; Laguna Hills, California · 106 sites in all
- Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced IllnessPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00672477 · 237 participants · Start Jun 2008 · Primary completion Feb 2013
Drug: Methylnaltrexone; Placebo · For: Opioid-Induced Constipation
Sites: Mobile, Alabama; Laguna Hills, California; Lancaster, California · 60 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death246
- drug ineffective208
- nausea118
- constipation113
- abdominal pain106
- pain84
- diarrhoea81
- vomiting77
- fatigue67
- headache58
- abdominal pain upper57
- off label use51
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2008 | 10 |
| 2009 | 38 |
| 2010 | 44 |
| 2011 | 61 |
| 2012 | 25 |
| 2013 | 25 |
| 2014 | 40 |
| 2015 | 49 |
| 2016 | 144 |
| 2017 | 166 |
| 2018 | 137 |
| 2019 | 217 |
| 2020 | 148 |
| 2021 | 109 |
| 2022 | 71 |
| 2023 | 62 |
| 2024 | 59 |
| 2025 | 61 |
| 2026 | 53 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Relistor* (Methylnaltrexone Bromide)
2024 spending
$135M
Beneficiaries
15,616
56,864 claims
Per beneficiary
$8,617
$52.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $82,678,459 |
| 2021 | $95,717,741 |
| 2022 | $117,077,748 |
| 2023 | $132,882,335 |
| 2024 | $134,570,150 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
Kistemaker KRJ, Sijani F, Brinkman DJ, et al. · Cancer Treat Rev 2024 · Meta-Analysis, Systematic Review
- The MOVEMENT Trial.
Holm M, Tornvall P, Henareh L, et al. · J Am Heart Assoc 2019 · Multicenter Study, Randomized Controlled Trial
- No Effect of Methylnaltrexone on Acute Pancreatitis Severity: A Multicenter Randomized Controlled Trial.
Knoph CS, Cook ME, Novovic S, et al. · Am J Gastroenterol 2024 · Randomized Controlled Trial, Multicenter Study
- Mu-opioid antagonists for opioid-induced bowel dysfunction.
McNicol ED, Boyce D, Schumann R, et al. · Cochrane Database Syst Rev 2008 · Systematic Review
- Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
Mehta N, O'Connell K, Giambrone GP, et al. · Postgrad Med 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Laxatives for the management of constipation in people receiving palliative care.
Candy B, Jones L, Larkin PJ, et al. · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Salix Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.